Tiffany Haynes’ Post

🎥 Take a look at this insightful interview with Dr. Michael Belin, Chief Medical Officer of Epion Therapeutics! At International Keratoconus Academy's Second Annual Keratoconus Symposium, Dr. Belin coached the audience in how to use the 𝗔𝗕𝗖𝗗 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗗𝗶𝘀𝗽𝗹𝗮𝘆 🔠, which he developed to classify disease severity and help diagnose keratoconus earlier. 𝗧𝗵𝗲 𝗕𝗲𝗹𝗶𝗻 𝗔𝗕𝗖𝗗 𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘂𝘀𝗲𝘀 𝗳𝗼𝘂𝗿 𝗸𝗲𝘆 𝗽𝗮𝗿𝗮𝗺𝗲𝘁𝗲𝗿𝘀 𝘁𝗼 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗲 𝗸𝗲𝗿𝗮𝘁𝗼𝗰𝗼𝗻𝘂𝘀 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻: 🅰 = Anterior radius of curvature 🅱 = Back (posterior radius of curvature) 🅲 = minimal Corneal thickness 🅳 = Distance visual acuity The ABCD Progression Display – available on the OCULUS, Inc. #Pentacam – allows physicians to track the progression of ectatic disease for up to 8 exams. 🩺👁️ This breakthrough could mean earlier detection and treatment with cross-linking, preserving vision for countless patients. 🌟 #Ophthalmology #Innovation #Keratoconus #PatientCare #MedicalAdvances

During Dry Eye Awareness month, I am excited to spotlight Oculis’ pioneering efforts in advancing innovative solutions for Dry Eye patients worldwide. With an estimated 300 million individuals affected by DED, a staggering 87% of patients express dissatisfaction with current treatment options due to the disease's heterogeneity. Aligned with Oculis commitment to Rethinking Ophthalmology, we recently shared promising data from the RELIEF trial for signs of DED. This represents a significant stride towards potentially transforming DED treatment through #PrecisionMedicine with OCS-02 (licaminlimab), an innovative anti-TNF-α antibody eye drop tailored for topical administration. The trial showed efficacy across various DED signs, with a remarkable 5 times greater treatment effect in signs for patients with a specific TNFR1-related genotype, which was consistent with the 7 times greater effect in symptoms observed in a previous trial in the same genotype population underscoring the unprecedented benefits of a predictive and personalized medicine approach. As we tackle the substantial unmet needs in DED, recognizing the disease's complexity and the diverse patient population, our primary focus remains on advancing #innovation in precision medicine to step change outcomes for patients. #DryEyeAwareness #Biotech #ClinicalTrials #EyeHealth #EyeDisease

Join the All Star Panelists, Arshad M. Khanani; Firas M. Rahhal, MD; Ram Palanki; George Magrath; and Maryam Mokhtarzadeh, M.D. at the Association for Research in Vision and Ophthalmology (ARVO) Special Interest Group (SIG) discussion on "Oral Medications for Management of Retinal Diseases". The session is being moderated by Charles DeBoer and myself. With many attempts to address to treatment burden for both patients and clinicians, oral medications appear to have become a significant focus as a likely treatment option for retinal diseases. This SIG will discuss the various programs and the background information about what it takes to plan and implement an oral med clinical study, various endpoints, what the regulators are likely to look at for approval, and what will it take to commercialize and market these products if and when they get approved. We also encourage the audience to partake in the discussion - we welcome questions and will raise these questions in front of the panel during the SIG. Feel free to ask any questions you may have. Join us for this interesting conversation - the SIG is on July 11, 2024, 3-430pm PST. If you haven't registered, please do so quickly. The panel and the moderators are looking forward to this event!

We are pleased to share a significant milestone in our journey at Cirrus Therapeutics, an ocular immunology-focused company my partner in crime Andrew Dick and I co-founded. Our recent research, published in #ScienceTranslationalMedicine, introduces a pioneering approach to treating age-related macular degeneration (#AMD). By enhancing IRAK-M protein levels in retinal cells, we have developed a promising new therapy for AMD, the leading cause of vision loss in older adults. This discovery, made in collaboration with esteemed researchers from the University of Bristol and the UCL Institute of Ophthalmology, including the super talented Jian Liu and Dave Copland, represents a pathway-agnostic solution offering comprehensive treatment options for dry AMD. This innovative approach aims to address the complex pathophysiology of AMD, providing hope to millions affected by this debilitating condition. We extend our gratitude to the Rosetrees Trust, Stoneygate Trust, Underwood Trust, Macular Society, Sight Research UK, NIHR Moorfields Biomedical Research Centre, UCL Institute of Ophthalmology, our other supporters who have made this research possible. Many thanks to our incredible advisors James Handa, Frank G. Holz, Brian Mansfield and Maritza McIntyre for their unwavering support and expert guidance. As we continue to advance our lead program and engage with investors, we remain committed to our mission of developing cutting-edge treatments for long-term eye diseases that can cause blindness. Read more about the publication here: https://lnkd.in/gFvJkdCE #Ophthalmology #VisionCare #ScientificResearch #CirrusTherapeutics #HealthcareInnovation

🌟 Exciting Announcement! 🌟 We are thrilled to share the publishing of our article: "Protocol of the LATFIA Trial (Laser Assisted Treatment of Fistula in Ano): A Multicentre, Prospective, Randomized Controlled Trial Comparing Fistula-Tract Laser Closure (FiLaC™) with Rectal Advancement Flap for High Trans-sphincteric Fistulas." 🔬 The LATFIA Trial represents a significant advancement in the field of proctology, offering insights into innovative treatment approaches for high trans-sphincteric fistulas. 📝 This meticulously planned and executed trial protocol provides a comprehensive framework for comparing the efficacy and safety of two prominent techniques: Fistula-Tract Laser Closure (FiLaC™) and Rectal Advancement Flap. 💡 By conducting a multicentre, prospective, randomized controlled trial, the LATFIA Trial aims to deliver robust evidence that will guide clinicians in making informed decisions regarding the optimal management of complex fistula-in-ano cases. 👥 We extend our gratitude to all the researchers, clinicians, and participants involved in making this trial possible. Your dedication and commitment to advancing medical science are truly commendable. 📖 Dive into the details of the LATFIA Trial protocol and join us in celebrating this milestone in the quest for improved treatments for fistula-in-ano. #MedicalResearch #FistulaTreatment #LATFIATrial #Coloproctology #ColorectalDisease #HealthcareAdvancement Colorectal Disease. https://lnkd.in/eQ4SEzd5 Jasper Stijns, Van den Broeck Sylvie,Bert Houben, Ben Gys, Els Van Dessel, Gabriele Bislenghi, Niels Komen, M.D., Ph.D

Check out this paper by scientists from Roche & MIT, carried out on AIM Biotech’s idenTx devices!

#ASRS2024: In real-world patients with age-related macular degeneration (AMD) associated geographic atrophy, intravitreal pegcetacoplan has an acceptable safety profile with rare complications leading to long-term vision loss, according to a poster presented at the ASRS – American Society of Retina Specialists meeting, held in Stockholm, July 17 to July 20, 2024. “Though randomized clinical trials are the gold standard for assessing the safety and efficacy of emerging therapeutics, they may not reflect the practice patterns, patient population and outcomes observed in routine clinical practice,” explains Janani Singaravelu, MS, MD. “Clinicians can utilize the additional insight provided by real world data to help guide clinical decision making.” Read here: https://brnw.ch/21wLsmg #AgeRelatedMacularDegeneration #GeographicAtrophy #EyeCare #IntravitrealPegcetacoplan #VisionLoss #ClinicalTrials #Ophthalmology

🚀 Exciting News in Healthcare Innovation! In a landscape where 4.3 million women annually face over 12 days of anticipation for biopsy results, CLISTEPROBE is revolutionizing the game. Our cutting-edge technology provides real-time disease type detection during breast biopsy procedures, transforming the narrative towards faster and more informed outcomes. 🌐 Notably, the impact of this ground breaking technology extends beyond human health—it holds the promise of advancing animal cancer diagnosis. 🐾 📑 And there's more! Attached is a paper showcasing another dimension of our innovation in the field of medicine—specifically in anaesthesia. Imagine sensors on a needle bringing about better outcomes and informed decisions. The possibilities are endless! Join us in shaping the future of healthcare. #HealthcareInnovation #CLISTEPROBE #FutureOfHealthcare #MedicalAdvancements 👩⚕️🐾 https://lnkd.in/eHBNMBnZ

Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal ·      Tacrosolv eye drops, a low-dose, aqueous Marinosolv-enabled formulation of Tacrolimus, are safe and effective in alleviating symptoms of allergic rhinoconjunctivitis ·      Data from phase II dose-finding clinical trial have been published in peer-reviewed Clinical Ophthalmology journal ·      Tacrosolv offers great potential in treatment of inflammatory diseases of the ocular surface Eva Prieschl-Grassauer, CSO of Marinomed, comments: “With our Marinosolv solubilization technology, we could significantly increase the solubility of Tacrolimus in a water-based formulation, thereby improving bioavailability, lowering the needed dose, and leading to a faster onset of action. The encouraging results of this clinical study show that Tacrosolv is a safe and effective treatment option for ocular inflammation. Tacrosolv has the potential to benefit a multitude of inflammatory eye diseases, where the currently limited treatment options create unmet medical need.” The publication is available here: https://lnkd.in/dbFaRsdb The full press release is available here: https://lnkd.in/dJWD_82x #Tacrosolv #Marinosolv #solubilization #formulationdevelopment #dryeye #ocularinflammation #oceanofideas #allergicrhinoconjunctivitis

Focused Ultrasound for Glioblastoma: The first two patients have been treated in Belgium in a new clinical trial comparing the use of Carthera’s SonoCloud-9 implantable ultrasound device plus chemotherapy to standard-of-care therapies in patients with recurrent glioblastoma. The study is set to recruit 560 participants across various locations in the US and Europe over the next two years. Discover more: https://bit.ly/3uEqGP5